

Company announcement

No. 22/2022

Orphazyme A/S in restructuringOle Maaløes Vej 3
DK-2200 Copenhagen Nwww.orphazyme.com

Company Registration No. 32266355

Updated Financial Calendar for 2022

Copenhagen, Denmark, April 28, 2022 – Orphazyme A/S in restructuring (ORPHA.CO; ORPH) (“Orphazyme” or the “Company”), a late-stage biopharmaceutical company, announces an update to the Company’s Financial Calendar for the remainder of 2022 following the current status of the in-court restructuring proceedings of the Company (please see company announcements no. 10/2022 and 11/2022).

Deadline for submission of shareholder proposals to Annual General Meeting

No later than six weeks prior to the Annual General Meeting 2022

Annual Report 2021

May 16, 2022

Annual General Meeting 2022

No later than 1 month after the completion of the ongoing in-court restructuring proceedings

Interim Report First Half 2022

August 25, 2022

For additional information, please contact**Orphazyme A/S in restructuring**

Anders Vadsholt, Chief Executive Officer and Chief Financial Officer +45 2898 9055

John Sommer Schmidt, Restructuring Administrator +45 8620 7500

About Orphazyme

Orphazyme is a late-stage biopharmaceutical company developing arimoclomol for Niemann-Pick disease type C (NPC). Orphazyme is headquartered in Denmark. Orphazyme’s shares are listed on Nasdaq Copenhagen (ORPHA).

About arimoclomol

Arimoclomol is an investigational drug candidate that amplifies the production of heat shock proteins (HSPs). HSPs can rescue defective misfolded proteins and improve the function of lysosomes. Arimoclomol is administered orally, and has now been studied in 10 Phase 1, four Phase 2, and three pivotal Phase 2/3 trials. Arimoclomol has received Orphan Drug Designation (ODD) for NPC in the US and EU. Arimoclomol has received Fast-Track Designation (FTD), Breakthrough Therapy Designation (BTD), and Rare Pediatric Disease Designation (RPDD) from the U.S. Food and Drug Administration (FDA) for NPC. On June 17, 2021, Orphazyme received a Complete Response Letter from the FDA regarding its New Drug Application for arimoclomol for the treatment of NPC. The Company plans to request a Type C Meeting with the FDA in Q2 2022.

Forward-looking statement

This company announcement may contain certain forward-looking statements under the U.S. Private Securities Litigation Reform Act of 1995 and otherwise, including forward-looking statements about the Company’s intention to file annual and interim reports in Denmark, and host an annual general meeting, and the timing thereof. Although the Company believes its expectations are based on reasonable assumptions, all statements other than statements of historical fact included in this company announcement about future events are subject to (i) change without notice and (ii) factors beyond the Company’s control, including pursuant to regulatory or judicial intervention. Except as required by law, the Company assumes no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.